Estimating quality adjusted progression free survival of first-line treatments for EGFR mutation positive non small cell lung cancer patients in The Netherlands

S. Cora Verduyn, Bonne Biesma, Franz M. N. H. Schramel, Feike W. van der Scheer, Merel K. Langenfeld, Maria A. de Peuter, Anne-Marie C. Dingemans

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)108
JournalHealth and Quality of Life Outcomes
Volume10
DOIs
Publication statusPublished - 10 Sep 2012

Keywords

  • Advanced non-small cell lung cancer
  • Tyrosine kinase inhibitors
  • EGFR mutation
  • Gefitinib
  • Quality of life
  • Progression free survival

Cite this